{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:38:30Z","timestamp":1792013910733,"version":"4.4.0"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ageing Research Reviews"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.arr.2018.03.003","type":"journal-article","created":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T02:20:38Z","timestamp":1520475638000},"page":"99-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["The neurochemistry of agitation in Alzheimer\u2019s disease: a systematic review"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7482-2758","authenticated-orcid":false,"given":"Kathy Y.","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisling E.","family":"Stringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8053-7024","authenticated-orcid":false,"given":"Suzanne J.","family":"Reeves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arr.2018.03.003_bib0005","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/gps.1316","article-title":"findings from the two-year longitudinal Maasbed study","volume":"20","author":"Aalten","year":"2005","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.arr.2018.03.003_bib0010","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/nrn2648","article-title":"Stress signalling pathways that impair prefrontal cortex structure and function","volume":"10","author":"Arnsten","year":"2009","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.arr.2018.03.003_bib0015","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1001\/archneur.61.8.1249","article-title":"Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease","volume":"61","author":"Assal","year":"2004","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.arr.2018.03.003_bib0020","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nrn1926","article-title":"Neuroleptic drugs in dementia: benefits and harm","volume":"7","author":"Ballard","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.arr.2018.03.003_bib0025","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nrneurol.2009.39","article-title":"Management of agitation and aggression associated with Alzheimer disease","volume":"5","author":"Ballard","year":"2009","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.arr.2018.03.003_bib0030","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0028-3908(99)00010-6","article-title":"A review of central 5-HT receptors and their function","volume":"38","author":"Barnes","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.arr.2018.03.003_bib0035","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0165-1781(93)90062-L","article-title":"Post-mortem examination of dopaminergic parameters in Alzheimer\u2019s disease: relationship to noncognitive symptoms","volume":"49","author":"Bierer","year":"1993","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.arr.2018.03.003_bib0040","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/00002093-198903030-00004","article-title":"Monoamine metabolites in cerebrospinal fluid and behavioral ratings in patients with early and late onset of Alzheimer dementia","volume":"3","author":"Br\u00e5ne","year":"1989","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.arr.2018.03.003_bib0045","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1097\/NEN.0b013e318232a379","article-title":"Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years","volume":"70","author":"Braak","year":"2011","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.arr.2018.03.003_bib0050","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1192\/bjp.157.1.86","article-title":"Psychiatric phenomena in Alzheimer\u2019s disease: IV: Disorders of behaviour","volume":"157","author":"Burns","year":"1990","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.arr.2018.03.003_bib0055","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1046\/j.1440-1681.1999.03151.x","article-title":"The ABC of GABA receptors: a brief review","volume":"26","author":"Chebib","year":"1999","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.arr.2018.03.003_bib0060","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1126\/science.6338589","article-title":"Alzheimer\u2019s disease: a disorder of cortical cholinergic innervation","volume":"219","author":"Coyle","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.arr.2018.03.003_bib0065","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1212\/WNL.47.4.876","article-title":"Neuropsychiatric aspects of Alzheimer\u2019s disease: the cholinergic hypothesis revisited","volume":"47","author":"Cummings","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2018.03.003_bib0070","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/0006-3223(93)90009-3","article-title":"Physostigmine ameliorates the delusions of Alzheimer\u2019s disease","volume":"33","author":"Cummings","year":"1993","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.arr.2018.03.003_bib0075","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1017\/S1041610214001963","article-title":"Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition","volume":"27","author":"Cummings","year":"2015","journal-title":"Int. Psychogeriatr."},{"key":"10.1016\/j.arr.2018.03.003_bib0080","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S0006-3223(00)01011-8","article-title":"Overview of nicotinic receptors and their roles in the central nervous system","volume":"49","author":"Dani","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.arr.2018.03.003_bib0085","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1126\/science.289.5479.591","article-title":"Dysfunction in the neural circuitry of emotion regulation\u2013a possible prelude to violence","volume":"289","author":"Davidson","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.arr.2018.03.003_bib0090","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00702-009-0243-8","article-title":"Neurotransmitters and prefrontal cortex-limbic system interactions: implications for plasticity and psychiatric disorders","volume":"116","author":"Del Arco","year":"2009","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.arr.2018.03.003_bib0095","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1037\/a0031544","article-title":"Revisiting the serotonin-aggression relation in humans: a meta-analysis","volume":"139","author":"Duke","year":"2013","journal-title":"Psychol. Bull."},{"key":"10.1016\/j.arr.2018.03.003_bib0100","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.neuint.2007.10.018","article-title":"The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia","volume":"52","author":"Engelborghs","year":"2008","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.arr.2018.03.003_bib0105","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S1734-1140(09)70132-X","article-title":"Overview on 5-HT receptors and their role in physiology and pathology of the central nervous system","volume":"61","author":"Filip","year":"2009","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.arr.2018.03.003_bib0110","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/sj.npp.1300330","article-title":"Differential involvement of 5-HT(1B\/1D) and 5-HT6 receptors in cognitive and non-cognitive symptoms in Alzheimer\u2019s disease","volume":"29","author":"Garcia-Alloza","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.arr.2018.03.003_bib0115","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.neuropsychologia.2004.06.007","article-title":"Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer\u2019s disease","volume":"43","author":"Garcia-Alloza","year":"2005","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.arr.2018.03.003_bib0120","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/j.1532-5415.1997.tb05969.x","article-title":"Psychotic symptoms and physically aggressive behavior in Alzheimer\u2019s disease","volume":"45","author":"Gilley","year":"1997","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.arr.2018.03.003_bib0125","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nrn3524","article-title":"Uncertainty and anticipation in anxiety: an integrated neurobiological and psychological perspective","volume":"14","author":"Grupe","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.arr.2018.03.003_bib0130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000085071","article-title":"Evaluating associations between 5-HTTLPR polymorphism and Alzheimer\u2019s disease for Korean patients","volume":"20","author":"Ha","year":"2005","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.arr.2018.03.003_bib0135","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.psyneuen.2004.02.001","article-title":"Growth hormone response to clonidine predicts aggression in Alzheimer\u2019s disease","volume":"29","author":"Herrmann","year":"2004","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.arr.2018.03.003_bib0140","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1176\/jnp.16.3.261","article-title":"The role of norepinephrine in the behavioral and psychological symptoms of dementia","volume":"16","author":"Herrmann","year":"2004","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.arr.2018.03.003_bib0145","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/hmg\/7.9.1507","article-title":"5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer\u2019s disease","volume":"7","author":"Holmes","year":"1998","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.arr.2018.03.003_bib0150","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/jnnp.71.6.777","article-title":"Psychosis and aggression in Alzheimer\u2019s disease: the effect of dopamine receptor gene variation","volume":"71","author":"Holmes","year":"2001","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.arr.2018.03.003_bib0155","doi-asserted-by":"crossref","first-page":"117","DOI":"10.5808\/GI.2012.10.2.117","article-title":"Sample size and statistical power calculation in genetic association studies","volume":"10","author":"Hong","year":"2012","journal-title":"Genomics Inform."},{"key":"10.1016\/j.arr.2018.03.003_bib0160","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/gps.418","article-title":"Guidelines for the management of agitation in dementia","volume":"16","author":"Howard","year":"2001","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.arr.2018.03.003_bib0165","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1192\/bjp.bp.115.177683","article-title":"Baseline characteristics and treatment-emergent risk factors associated with cerebrovascular event and death with risperidone in dementia patients","volume":"209","author":"Howard","year":"2016","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.arr.2018.03.003_bib0170","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/344062a0","article-title":"Interaction between neuropeptide Y and noradrenaline on central catecholamine neurons","volume":"344","author":"Illes","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.arr.2018.03.003_bib0175","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0006-8993(03)02554-X","article-title":"Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease","volume":"974","author":"Lai","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/j.arr.2018.03.003_bib0180","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00213-010-1936-2","article-title":"Differential involvement of hippocampal serotonin1A receptors and re-uptake sites in non-cognitive behaviors of Alzheimer\u2019s disease","volume":"213","author":"Lai","year":"2011","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.arr.2018.03.003_bib0185","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/gps.1109","article-title":"5-HT2A T102C receptor polymorphism and neuropsychiatric symptoms in Alzheimer\u2019s disease","volume":"19","author":"Lam","year":"2004","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.arr.2018.03.003_bib0190","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.mad.2005.09.016","article-title":"Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer\u2019s disease","volume":"127","author":"Lanari","year":"2006","journal-title":"Mech. Ageing Dev."},{"key":"10.1016\/j.arr.2018.03.003_bib0195","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1176\/jnp.13.1.5","article-title":"Role of serotonin in the behavioral and psychological symptoms of dementia","volume":"13","author":"Lanct\u00f4t","year":"2001","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.arr.2018.03.003_bib0200","first-page":"646","article-title":"Central serotonergic activity is related to the aggressive behaviors of Alzheimer\u2019s disease","volume":"27","author":"Lanct\u00f4t","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.arr.2018.03.003_bib0205","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/gps.636","article-title":"Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer\u2019s disease","volume":"17","author":"Lanct\u00f4t","year":"2002","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.arr.2018.03.003_bib0210","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/070674370404900705","article-title":"GABAergic function in Alzheimer\u2019s disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia","volume":"49","author":"Lanct\u00f4t","year":"2004","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.arr.2018.03.003_bib0215","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1017\/S1041610206003899","article-title":"Behavioral correlates of GABAergic disruption in Alzheimer\u2019s disease","volume":"19","author":"Lanct\u00f4t","year":"2007","journal-title":"Int. Psychogeriatr."},{"key":"10.1016\/j.arr.2018.03.003_bib0220","first-page":"53","article-title":"The serotonergic system in Alzheimer\u2019s disease and normal neocortical post-mortem brain: neurochemical and clinical correlates","volume":"2","author":"Leake","year":"1993","journal-title":"Neurol. Psychiatry Brain Res."},{"key":"10.1016\/j.arr.2018.03.003_bib0225","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.neubiorev.2017.10.023","article-title":"Magnetic resonance imaging of the human locus coeruleus: a systematic review","volume":"83","author":"Liu","year":"2017","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.arr.2018.03.003_bib0230","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1192\/bjp.bp.113.141119","article-title":"Non-pharmacological interventions for agitation in dementia: systematic review of randomised controlled trials","volume":"205","author":"Livingston","year":"2014","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.arr.2018.03.003_bib0235","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1468-1331.1996.tb00209.x","article-title":"Relationship between CSF neurotransmitter metabolites and aggressive behavior in Alzheimer\u2019s disease","volume":"3","author":"Lopez","year":"1996","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.arr.2018.03.003_bib0240","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1176\/appi.ajp.157.5.708","article-title":"Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging","volume":"157","author":"Lyketsos","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.arr.2018.03.003_bib0245","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0006-3223(01)01235-5","article-title":"Noradrenergic changes, aggressive behavior, and cognition in patients with dementia","volume":"51","author":"Matthews","year":"2002","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.arr.2018.03.003_bib0250","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1212\/WNL.55.10.1460","article-title":"Cholinergic deficits contribute to behavioral disturbance in patients with dementia","volume":"55","author":"Minger","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2018.03.003_bib0255","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/00002093-199601040-00005","article-title":"Correlation between clinical characteristics and cerebrospinal fluid neuropeptide Y levels in dementia of the Alzheimer type and frontotemporal dementia","volume":"10","author":"Minthon","year":"1996","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.arr.2018.03.003_bib0260","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0006-3223(98)00004-3","article-title":"Fenfluramine challenge test as a marker of serotonin activity in patients with Alzheimer\u2019s dementia and agitation","volume":"44","author":"Mintzer","year":"1998","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.arr.2018.03.003_bib0265","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2463\/mrms.7.205","article-title":"Visualization of neuromelanin in the Substantia nigra and locus ceruleus at 1.5T using a 3D-gradient echo sequence with magnetization transfer contrast","volume":"7","author":"Nakane","year":"2008","journal-title":"Magn. Reson. Med. Sci."},{"key":"10.1016\/j.arr.2018.03.003_bib0270","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.neuroimage.2004.06.030","article-title":"For better or for worse: neural systems supporting the cognitive down- and up-regulation of negative emotion","volume":"23","author":"Ochsner","year":"2004","journal-title":"Neuroimage"},{"key":"10.1016\/j.arr.2018.03.003_bib0275","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1532-5415.2011.03314.x","article-title":"Neuropsychiatric symptoms and the risk of institutionalization and death: the aging, demographics, and memory study","volume":"59","author":"Okura","year":"2011","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.arr.2018.03.003_bib0280","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1196\/annals.1330.022","article-title":"Serotonin and aggression","volume":"1036","author":"Olivier","year":"2004","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.arr.2018.03.003_bib0285","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0893-133X(98)00054-2","article-title":"Cerebrospinal fluid epinephrine in Alzheimer\u2019s disease and normal aging","volume":"19","author":"Peskind","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.arr.2018.03.003_bib0290","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1176\/appi.ajp.2014.14040480","article-title":"Neuropsychiatric symptoms as predictors of progression to severe Alzheimer\u2019s dementia and death: the Cache County Dementia Progression Study","volume":"172","author":"Peters","year":"2015","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.arr.2018.03.003_bib0295","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/0891988715601735","article-title":"Citalopram for the treatment of agitation in Alzheimer dementia: genetic influences","volume":"29","author":"Peters","year":"2016","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"10.1016\/j.arr.2018.03.003_bib0300","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/jama.2014.93","article-title":"Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial","volume":"311","author":"Porsteinsson","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.arr.2018.03.003_bib0305","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.neurobiolaging.2006.10.011","article-title":"Role of 5HT2A and 5HT2C polymorphisms in behavioural and psychological symptoms of Alzheimer\u2019s disease","volume":"29","author":"Pritchard","year":"2008","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.arr.2018.03.003_bib0310","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/gps.2214","article-title":"Investigation of dopamine receptors in susceptibility to behavioural and psychological symptoms in Alzheimer\u2019s disease","volume":"24","author":"Pritchard","year":"2009","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.arr.2018.03.003_bib0315","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/BF00993268","article-title":"Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms","volume":"17","author":"Procter","year":"1992","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.arr.2018.03.003_bib0320","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.neurobiolaging.2010.06.011","article-title":"Association of serotonin and dopamine gene pathways with behavioral subphenotypes in dementia","volume":"33","author":"Proitsi","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.arr.2018.03.003_bib0325","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.neulet.2014.06.034","article-title":"Decreased platelet serotonin concentration in Alzheimer\u2019s disease with involuntary emotional expression disorder","volume":"578","author":"Prok\u0161elj","year":"2014","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.arr.2018.03.003_bib0330","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1212\/01.wnl.0000341932.21961.f3","article-title":"Increased striatal dopamine (D2\/D3) receptor availability and delusions in Alzheimer disease","volume":"72","author":"Reeves","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2018.03.003_bib0335","doi-asserted-by":"crossref","first-page":"908915","DOI":"10.1155\/2014\/908915","article-title":"Global epidemiology of dementia: Alzheimer\u2019s and vascular types","volume":"2014","author":"Rizzi","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.arr.2018.03.003_bib0340","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mam.2015.05.005","article-title":"Neuropsychiatric symptoms in Alzheimer\u2019s disease: what might be associated brain circuits","volume":"43\u201344","author":"Rosenberg","year":"2015","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.arr.2018.03.003_bib0345","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1146\/annurev.pharmtox.44.101802.121429","article-title":"Analysis of GABAA receptor function and dissection of the pharmacology of benzodiazepines and general anesthetics through mouse genetics","volume":"44","author":"Rudolph","year":"2004","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.arr.2018.03.003_bib0350","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1523\/JNEUROSCI.17-14-05573.1997","article-title":"Adrenergic receptors in Alzheimer\u2019s disease brain: selective increases in the cerebella of aggressive patients","volume":"17","author":"Russo-Neustadt","year":"1997","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2018.03.003_bib0355","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2174\/157015908785777229","article-title":"Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part I: principles of functional organisation","volume":"6","author":"Samuels","year":"2008","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.arr.2018.03.003_bib0360","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3233\/JAD-2009-1054","article-title":"Dopamine D3 receptor gene polymorphism influences on behavioral and psychological symptoms of dementia (BPSD) in mild dementia of Alzheimer\u2019s type","volume":"17","author":"Sato","year":"2009","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2018.03.003_bib0365","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0165-1781(88)90101-1","article-title":"Platelet tritiated imipramine binding and MAO activity in Alzheimer\u2019s disease patients with agitation and delusions","volume":"25","author":"Schneider","year":"1988","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.arr.2018.03.003_bib0370","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/01.JGP.0000200589.01396.6d","article-title":"Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials","volume":"14","author":"Schneider","year":"2006","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.arr.2018.03.003_bib0375","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.avb.2008.06.003","article-title":"Role of serotonin and dopamine system interactions in the neurobiology of impulsive aggression and its comorbidity with other clinical disorders","volume":"13","author":"Seo","year":"2008","journal-title":"Aggress. Violent Behav."},{"key":"10.1016\/j.arr.2018.03.003_bib0380","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/01.JGP.0000237065.78966.1b","article-title":"Aggressive behavior and neuroleptic medication are associated with increased number of alpha1-adrenoceptors in patients with Alzheimer disease","volume":"15","author":"Sharp","year":"2007","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.arr.2018.03.003_bib0385","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s002130000532","article-title":"Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study","volume":"152","author":"Silvestri","year":"2000","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.arr.2018.03.003_bib0390","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1001\/archneur.58.9.1425","article-title":"The 5-HTTPR*S\/*L polymorphism and aggressive behavior in Alzheimer disease","volume":"58","author":"Sukonick","year":"2001","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.arr.2018.03.003_bib0395","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jagp.2016.11.011","article-title":"Cholinergic receptor binding in Alzheimer disease and healthy aging: assessment In vivo with positron emission tomography imaging","volume":"25","author":"Sultzer","year":"2017","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.arr.2018.03.003_bib0400","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0006-3223(97)00146-7","article-title":"Association of plasma homovanillic acid with behavioral symptoms in patients diagnosed with dementia: a preliminary report","volume":"42","author":"Sweet","year":"1997","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.arr.2018.03.003_bib0405","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/archneur.55.10.1335","article-title":"Dopamine receptor genetic variation, psychosis, and aggression in Alzheimer disease","volume":"55","author":"Sweet","year":"1998","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.arr.2018.03.003_bib0410","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1017\/S1041610201007827","article-title":"The 5-HTTPR polymorphism confers liability to a combined phenotype of psychotic and aggressive behavior in Alzheimer disease","volume":"13","author":"Sweet","year":"2001","journal-title":"Int. Psychogeriatr."},{"key":"10.1016\/j.arr.2018.03.003_bib0415","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1176\/ajp.155.1.54","article-title":"Efficacy and tolerability of carbamazepine for agitation and aggression in dementia","volume":"155","author":"Tariot","year":"1998","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.arr.2018.03.003_bib0420","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jalz.2016.06.2362","article-title":"Locus coeruleus volume and cell population changes during Alzheimer\u2019s disease progression: a stereological study in human postmortem brains with potential implication for early-stage biomarker discovery","volume":"13","author":"Theofilas","year":"2016","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.arr.2018.03.003_bib0425","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1517\/14728222.11.4.527","article-title":"The 5-HT3 receptor as a therapeutic target","volume":"11","author":"Thompson","year":"2007","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.arr.2018.03.003_bib0430","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3233\/JAD-2007-12306","article-title":"Serotonin transporter gene polymorphism and BPSD in mild Alzheimer\u2019s disease","volume":"12","author":"Ueki","year":"2007","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2018.03.003_bib0435","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3233\/JAD-140309","article-title":"Brain region-specific monoaminergic correlates of neuropsychiatric symptoms in Alzheimer\u2019s disease","volume":"41","author":"Vermeiren","year":"2014","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2018.03.003_bib0440","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1016\/j.neurobiolaging.2014.05.031","article-title":"Monoaminergic neurotransmitter alterations in postmortem brain regions of depressed and aggressive patients with Alzheimer\u2019s disease","volume":"35","author":"Vermeiren","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.arr.2018.03.003_bib0445","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.3233\/JAD-160320","article-title":"Brain serotonergic and noradrenergic deficiencies in behavioral variant frontotemporal dementia compared to early-onset Alzheimer\u2019s disease","volume":"53","author":"Vermeiren","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2018.03.003_bib0450","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1097\/JGP.0b013e3181ab8c61","article-title":"Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression","volume":"17","author":"Wang","year":"2009","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.arr.2018.03.003_bib0455","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000118256","article-title":"Alzheimer\u2019s disease and serotonin: a review","volume":"15","author":"Whitford","year":"1986","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.arr.2018.03.003_bib0460","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1002\/hbm.20687","article-title":"Aggression is related to frontal serotonin-1A receptor distribution as revealed by PET in healthy subjects","volume":"30","author":"Witte","year":"2009","journal-title":"Hum. Brain Mapp."},{"key":"10.1016\/j.arr.2018.03.003_bib0465","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0166-2236(96)10073-4","article-title":"Presynaptic nicotinic ACh receptors","volume":"20","author":"Wonnacott","year":"1997","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.arr.2018.03.003_bib0470","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jagp.2012.11.022","article-title":"Dronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients with noncognitive behavioral symptoms","volume":"22","author":"Woodward","year":"2014","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.arr.2018.03.003_bib0475","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2174\/1568007043482561","article-title":"5-ht6 receptors","volume":"3","author":"Woolley","year":"2004","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"key":"10.1016\/j.arr.2018.03.003_bib0480","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2174\/1568007043482561","article-title":"5-ht6 receptors","volume":"3","author":"Woolley","year":"2004","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"key":"10.1016\/j.arr.2018.03.003_bib0485","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejphar.2005.10.004","article-title":"Escalated aggressive behavior: dopamine, serotonin and GABA","volume":"526","author":"de Almeida","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.arr.2018.03.003_bib0490","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.bp.114.148403","article-title":"Longitudinal course of behavioural and psychological symptoms of dementia: systematic review","volume":"209","author":"van der Linde","year":"2016","journal-title":"Br. J. Psychiatry"}],"container-title":["Ageing Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163717302908?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163717302908?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T09:23:48Z","timestamp":1570872228000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568163717302908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":98,"alternative-id":["S1568163717302908"],"URL":"https:\/\/doi.org\/10.1016\/j.arr.2018.03.003","relation":{},"ISSN":["1568-1637"],"issn-type":[{"value":"1568-1637","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The neurochemistry of agitation in Alzheimer\u2019s disease: a systematic review","name":"articletitle","label":"Article Title"},{"value":"Ageing Research Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arr.2018.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}